SAN FRANCISCO, April 2, 2013 /PRNewswire/ -- GZS, Inc., a leader in developing disease-specific and condition-specific Electronic Medical Records/Electronic Health Records (EMR/EHR) and patient registry software solutions, has announced the worldwide release of the WebTracker-Hemophilia™ EHR patient registry solution used under the new brand name HemaGlobal™.
With the release of HemaGlobal, outcomes studies can be conducted on a global scale for the first time. The EMR/EHR patient registry system is used by virtually all Hemophilia Treatment Centers (HTC) in the U.S. to treat patients with bleeding and clotting disorders and to report high quality de-identified patient data to the Centers for Disease Control and Prevention (CDC).
HemaGlobal is a full-purpose EMR/EHR patient registry system that serves as a stable, scalable platform for integrating data from multiple sources, such as from pharmacies, laboratories, clinics and record archives, and in industry standard formats, including popular front-office applications and mainframe applications with HL-7 interface connectivity.
HemaGlobal is an ultra-secure web-based solution that can be used on the worldwide web or private intranets, and is intended for government agencies, ministries of health, non-government organizations, universities, treatment centers and healthcare providers throughout the world.
"After years of working closely with physicians and universities to develop a robust EHR patient registry solution for bleeding disorders here in the U.S., we are pleased and excited to extend our success to the rest of the world and truly globalize our understanding of this condition," said Dan Davis, Chief Executive Officer of GZS, Inc. "We are fortunate that we have found industry to be supportive of efforts to upgrade and standardize on global EHR patient registry applications."
The U.S. consortium of Hemophilia Treatment Centers use the EHR patient registry system as the national information infrastructure for creating and submitting surveillance reports for the CDC's Universal Data Collection (UDC), the Hemophilia Data Set to Maternal and Child Health (MCHB), Healthy People 2020 outcomes and adverse-event reports to the U.S. Food and Drug Administration (FDA).
HemaGlobal covers a large spectrum of bleeding and clotting disorders, including von Willebrand disease, congenital afibrinogenemia, Glanzmann's thrombasthenia, Bernard-Soulier syndrome, hemophilia and other factor deficiencies.
HemaGlobal makes it easy for hemophilia treatment centers to organize, analyze and manage patient information in detail using standardized nomenclature. It establishes a secure and timely data exchange that enables physicians to eliminate traditional IT and procedural bottlenecks as they share patient information with multi-disciplinary team members. The user interface is intuitive and requires little more than basic computing skills.
In the early 1980s, the CDC referred to San Francisco as "Ground Zero" in the AIDS epidemic. We embraced the name "Ground Zero Software" and launched *Lab Tracker™ for HIV, our first Electronic Medical Record (EMR), in 1993.
Since then, GZS has been a pioneer and leader in developing disease-specific and condition-specific EMR/EHR patient registry software solutions to the worldwide healthcare industry. The company's current product offerings are specific to Hemophilia and bleeding disorders, Spina Bifida, and are readily adapted to other diseases and conditions. GZS has a large customer base of universities, government and non-government organizations, pharmaceutical, diagnostics, and healthcare providers of all sizes in the U.S., South America and Africa.
*Lab Tracker-HIV was acquired by Virco Labs, Inc. (now Janssen Diagnostics, Inc.) in December, 2009
HemaGlobal™ and HemoGlobal™ are registered trademarks of Ground Zero Software, Inc.
GZS Corporate Communications